Cetrelimab boosts erdafitinib response in advanced urothelial carcinoma

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Springer Healthcare

Cetrelimab boosts erdafitinib response in advanced urothelial carcinoma

Oncology Urinary Bladder Cancer ESMO-2021

Description

Srikala Sridhar comments on the interim analysis of the NORSE study of first-line erdafitinib plus cetrelimab in cisplatin-ineligible patients with advanced urothelial carcinoma and fibroblast growth factor receptor alterations.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.